Novavax’s updated protein-based non-mRNA COVID-19 vaccine is now available for use in Poland for the prevention of COVID-19 in individuals aged 12 and older. Doses have been distributed by the appropriate Polish authorities and made available for this season’s vaccination campaign. The Novavax vaccine is currently the only updated COVID-19 vaccine option available in Poland.
We are pleased that our updated vaccine is available in time for the upcoming Christmas and winter holiday season. We are honored to support both the Polish government and the country’s healthcare workers to help protect Polish citizens and their loved ones against COVID-19. Starting today, individuals across the country can receive an updated vaccine.
Non-clinical data showed that Novavax’s updated COVID-19 vaccine induced functional immune responses against XBB.1.5, XBB.1.16 and XBB.2.3 variants. Additional non-clinical data demonstrated that Novavax’s vaccine induced neutralizing antibody responses to subvariants BA.2.86, EG.5.1, FL.1.5.1 and XBB.1.16.6 as well as CD4+ polyfunctional cellular (T-cell) responses against EG.5.1 and XBB.1.16.6. These data indicate Novavax’s vaccine can stimulate both arms of the immune system and may induce a broad response against currently circulating variants.1,2